Navigation Links
Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin
Date:11/9/2009

NANJING, China, Nov. 9 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement to acquire the manufacturing license in China of Rosuvastatin from Tianjin Tianda Pharmaceutical Co., Ltd. ("Tianda"). The acquisition of the manufacturing license will be effected through the acquisition of equity in Tianda as well as transfer of certain technologies from Tianda. Rosuvastatin was first marketed by Astrazeneca as Crestor in 2003 and is an effective statin to treat high cholesterol and related conditions.

Upon completion of the acquisition, Simcere will start manufacturing Rosuvastatin.

Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group commented on the agreement, "We are delighted to join forces with Tianda to manufacture Rosuvastatin in China. Rosuvastatin has huge market potential and we believe that with our marketing expertise we can help more heart disease patients in China benefit from this drug."

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Further information regarding these and other risks is included in Simcere's filings with the U.S. Securities and Exchange Commission at http://www.sec.gov . Simcere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells anti-infective medication, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .

SOURCE Simcere Pharmaceutical Group


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
2. Simcere Pharmaceutical Group Reports Third Quarter 2007 Results
3. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
4. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results
5. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
6. Simcere Pharmaceutical Group to Announce First Quarter 2008 Earnings on Tuesday, May 6, 2008
7. Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd.
8. Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin
9. Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results
10. Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008
11. Simcere Pharmaceutical Group Seeking Approval to Manufacture and Sell Influenza Drug zanamivir
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... Expert mattress researchers and testers ... in September, 2014 Sleepopolis has resided at Sleepopolis-mattress-reviews.com . The move signals ... mattress toppers, bed frames, and more. , Founder and Editor-in-Chief Derek Hales said, ...
(Date:5/6/2016)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written a new ... the Bible about helping to stop cancer. Yisrayl says there are too many suffering and ... health and science industries will pay close attention and take action. The Pastor says that ...
(Date:5/6/2016)... Lehi, Utah (PRWEB) , ... May 06, 2016 ... ... Career Step, an online provider of career-focused education and corporate training, and the ... families, are pleased to announce Maritza Aquino as the second full-tuition scholarship recipient ...
(Date:5/6/2016)... ... May 06, 2016 , ... Kenneth Cochran, DSc, RN, ... Institute of the South announced today that Dr. Robert Menuet, Interventional Cardiologist with ... Intravascular Ultrasound Guided Coronary Atherectomy. , This procedure involves the removal ...
(Date:5/6/2016)... Washington, DC (PRWEB) , ... May 06, 2016 ... ... Blum, Executive Vice President at CareFirst Blue Cross BlueShield and Former Principal Deputy ... Officer at CareMore - an Anthem Company; Steve Ondra, MD, Chief Medical Officer ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 3, 2016  As a teenager, an active and ... which damaged his heart. He continued enjoying sports and ... 2013, Shepherd,s heart was giving out and he was ... 20, 2013, the Mesa, Arizona ... Like a heart transplant, the SynCardia TAH-t is the ...
(Date:5/3/2016)... watching a film or TV show in high definition, you may not be familiar with ...  is a renowned authorized reseller of the medical industry,s top brands as well as a ... ... ... Although initially introduced ...
(Date:5/3/2016)... May 3, 2016 Pharmaceutical giant ... million to a woman who says its talc-based powder ... Gloria Ristesund $5 million in compensatory damages ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , This ... the company. In February, the same court awarded $72 ...
Breaking Medicine Technology: